Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623996 · ClinicalTrials.gov registry record · Phase 1
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04623996 is a Phase 1 study that was terminated before completion, run by Sumitomo Pharma America. The registered enrollment target is 2 participants.
The verdict
NCT04623996, a Phase 1 study, was terminated before completion, sponsored by Sumitomo Pharma America.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will evaluate preliminary safety and efficacy of TP-0184 to treat anemia when administered to adult patients with Revised International Prognostic Scoring System (IPSS-R) low or intermediate risk MDS. The recommended Phase 2 dose (RP2D) will be determined by the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the Phase 1 portion of the study.
Interventions
- DRUG TP-0184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2021-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623996
The ClinicalTrials.gov registry entry for NCT04623996 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TP-0184 is the first listed.
NCT04623996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04623996 about?
NCT04623996 is a clinical study titled "A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS". This study will evaluate preliminary safety and efficacy of TP-0184 to treat anemia when administered to adult patients with Revised International Prognostic Scoring System (IPSS-R) low or intermediate risk MDS. The recommended Phase 2 dose (RP2D) will be determined by the maximum tolerated dose (MT...
What is the current status of trial NCT04623996?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2020-12-28. Estimated completion is 2021-04-27.
What interventions are being tested in trial NCT04623996?
The interventions under investigation include: TP-0184 (DRUG).
Who is sponsoring clinical trial NCT04623996?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.